GEN Exclusives

More »

GEN News Highlights

More »
Nov 1, 2006

Roche Issues Two Milestone Payments

  • Memory Pharmaceuticals received a $2-million milestone from Roche related to MEM 3454. This is Memory’s lead compound for the treatment of neurological and psychiatric disorders. It is a result of the companies' alliance focused on the discovery and clinical development of nicotinic alpha-7 receptor agonists. Roche also elected to maintain its option to obtain an exclusive license for MEM 3454.

    Separately, Amira Pharmaceuticals received its first milestone payment from Roche nine months after the start of their research collaboration. The payment is the result of a collaboration in the field of inflammatory disease. Amira has identified a series of drug candidates against one mutually agreed target.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Mindclones and Immortality

Is the idea of making a software copy of a human mind something in the realm of reality or science fiction?